X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6404) 6404
Publication (1021) 1021
Book Review (98) 98
Book Chapter (65) 65
Conference Proceeding (11) 11
Dissertation (11) 11
Book / eBook (2) 2
Data Set (2) 2
Government Document (2) 2
Newsletter (2) 2
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4327) 4327
index medicus (4124) 4124
bortezomib (3342) 3342
oncology (2041) 2041
proteasome inhibitors (2012) 2012
animals (1918) 1918
apoptosis (1651) 1651
cancer (1416) 1416
proteasome endopeptidase complex - metabolism (1397) 1397
proteasome (1239) 1239
multiple myeloma (1230) 1230
cell line, tumor (1213) 1213
female (1109) 1109
male (1067) 1067
antineoplastic agents - pharmacology (1038) 1038
boronic acids - pharmacology (1027) 1027
hematology (1015) 1015
pyrazines - pharmacology (987) 987
mice (952) 952
proteins (935) 935
multiple myeloma - drug therapy (897) 897
apoptosis - drug effects (893) 893
proteasome inhibitor (883) 883
cell biology (858) 858
biochemistry & molecular biology (838) 838
ubiquitin (817) 817
multiple-myeloma (811) 811
antineoplastic agents - therapeutic use (792) 792
nf-kappa-b (756) 756
article (712) 712
proteasome inhibitor bortezomib (685) 685
boronic acids - therapeutic use (674) 674
proteasome inhibitors - pharmacology (672) 672
pyrazines - therapeutic use (664) 664
middle aged (643) 643
pharmacology & pharmacy (601) 601
research (588) 588
activation (568) 568
aged (566) 566
expression (547) 547
analysis (509) 509
care and treatment (504) 504
therapy (500) 500
chemotherapy (496) 496
degradation (491) 491
health aspects (479) 479
adult (459) 459
treatment outcome (456) 456
cells (453) 453
ubiquitin-proteasome system (451) 451
protease inhibitors - pharmacology (436) 436
antineoplastic combined chemotherapy protocols - therapeutic use (433) 433
proteasome inhibition (432) 432
proteolysis (422) 422
cell proliferation - drug effects (414) 414
signal transduction (402) 402
boronic acids - administration & dosage (396) 396
ubiquitin - metabolism (393) 393
pyrazines - administration & dosage (390) 390
proteasome inhibitors - therapeutic use (380) 380
dose-response relationship, drug (372) 372
drug therapy (370) 370
multiple myeloma - pathology (368) 368
pathway (368) 368
inhibitors (362) 362
gene expression (361) 361
proteasomes (351) 351
in-vitro (349) 349
neoplasms - drug therapy (349) 349
autophagy (344) 344
in-vivo (344) 344
drug synergism (339) 339
tumors (326) 326
ubiquitination (325) 325
medicine (320) 320
cell cycle (319) 319
physiological aspects (318) 318
cell survival - drug effects (315) 315
multiple-myeloma cells (310) 310
20s proteasome (307) 307
multidisciplinary sciences (306) 306
protease inhibitors - therapeutic use (305) 305
research article (305) 305
hemic and lymphatic diseases (303) 303
dexamethasone (301) 301
signal transduction - drug effects (301) 301
carfilzomib (299) 299
inhibition (297) 297
phosphorylation (293) 293
biology (282) 282
nf-kappa b - metabolism (280) 280
genetic aspects (279) 279
immunology (278) 278
survival (277) 277
unfolded protein response (274) 274
boronic acids - adverse effects (271) 271
drug resistance, neoplasm (270) 270
induced apoptosis (269) 269
pyrazines - adverse effects (269) 269
transplantation (265) 265
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6361) 6361
Japanese (28) 28
German (17) 17
French (16) 16
Chinese (14) 14
Korean (10) 10
Russian (9) 9
Polish (7) 7
Czech (5) 5
Hungarian (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 07/2008, Volume 14, Issue 7, pp. 748 - 755
Journal Article
Biomarker Research, ISSN 2050-7771, 03/2013, Volume 1, Issue 1, pp. 13 - 13
The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has... 
Bortezomib | PSMB5 | Drug resistance | Proteasome inhibitor | Mechanism | Chymotrypsin | Drug resistance in microorganisms | Lymphomas
Journal Article
Journal Article
Blood, ISSN 0006-4971, 04/2007, Volume 109, Issue 8, pp. 3177 - 3188
Journal Article
The Journal of Immunology, ISSN 0022-1767, 11/2009, Volume 183, Issue 10, pp. 6145 - 6150
Journal Article
BBA - General Subjects, ISSN 0304-4165, 06/2019, Volume 1863, Issue 6, pp. 1108 - 1115
Proteasomes play a key role in maintaining cellular homeostasis by the proteolytic removal of proteins, including ubiquitinated proteins and/or... 
Oxidative stress | Protein degradation | Testicular damage | SOD1 | Proteasome | CELLS | ACTIVATION | PROTEIN AGGREGATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | OXIDIZED PROTEINS | 26S PROTEASOME | P62 | IMPAIRMENT | BIOPHYSICS | 20S | DEGRADATION | Proteins | Superoxide | Bortezomib | Cell death | Proteolysis
Journal Article
FASEB Journal, ISSN 0892-6638, 01/2018, Volume 32, Issue 1, pp. 52 - 62
Bone atrophy and its related fragility fractures are frequent, late side effects of radiotherapy in cancer survivors and have a detrimental impact on their... 
Irradiation | Osteoblast | Bone | DNA repair | Apoptosis | MULTIPLE-MYELOMA | SYSTEM | TARGET | BIOCHEMISTRY & MOLECULAR BIOLOGY | apoptosis | DEPENDENT PROTEIN-KINASE | bone | osteoblast | irradiation | CELL BIOLOGY | PATHWAY | BIOLOGY | DNA-REPAIR | NF-KAPPA-B | Radiation Injuries - drug therapy | Apoptosis - drug effects | Apoptosis - radiation effects | Humans | Male | Osteoporosis - drug therapy | Bone Remodeling - radiation effects | Bortezomib - pharmacology | X-Ray Microtomography | Bone Remodeling - drug effects | Osteoporosis - metabolism | Radiation-Protective Agents - pharmacology | Cell Line | Cell Survival - drug effects | DNA Repair - drug effects | Osteoblasts - radiation effects | Proteasome Inhibitors - pharmacology | Mice, Inbred C57BL | Osteoblasts - drug effects | Mice, Transgenic | Osteoblasts - pathology | Animals | Osteoporosis - pathology | Radiation Injuries - pathology | Mice | Radiation Injuries - metabolism | 3T3 Cells | Ubiquitin | Adipose tissue | DNA damage | Radiation | SOST protein | Kinases | Bone (trabecular) | Osteoblasts | Proteins | Atrophy | Osteoporosis | Bone histomorphometry | Bone marrow | Biocompatibility | Catalysis | Repair | Parathyroid | Deoxyribonucleic acid--DNA | Radiation effects | Bortezomib | Cell survival | Bioassay | Pharmacology | Radiation therapy | Chemical compounds | Survival | Proteasome inhibitors | Quality of life | Fragility | Side effects | DNA-dependent protein kinase | Fractures | Inhibitors | Damage detection | Parathyroid hormone | Osteoclasts | Radiation damage | Cancer | Research
Journal Article
International Journal of Cancer, ISSN 0020-7136, 08/2015, Volume 137, Issue 3, pp. 686 - 697
Around 70% of breast cancers express the estrogen receptor α (ERα) and depend on estrogen for growth, survival and disease progression. The presence of hormone... 
Her2 inhibition | proteasome inhibition | estrogen receptor alpha inhibition | SURVIVAL | ACTIVATION | TAMOXIFEN | ER-ALPHA | ENDOCRINE TREATMENT | REPRESSION | ONCOLOGY | GROWTH | GENE-EXPRESSION | RESISTANCE | PROMOTES | Receptors, Estrogen - metabolism | Prognosis | TOR Serine-Threonine Kinases - metabolism | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Tumor Suppressor Protein p53 - genetics | Breast Neoplasms - metabolism | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Estrogen Receptor alpha - metabolism | Female | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Disease Models, Animal | Bortezomib | Receptors, Estrogen - genetics | Proteasome Inhibitors - pharmacology | Signal Transduction | Tumor Suppressor Protein p53 - metabolism | Breast Neoplasms - drug therapy | Proteasome Inhibitors - therapeutic use | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - pathology | Cell Line, Tumor | Breast Neoplasms - mortality | Pyrazines - pharmacology | Boronic Acids - pharmacology | Mitogen-Activated Protein Kinases - metabolism | Estrogen | Phenols | Development and progression | Breast cancer | Hormones | Tumor proteins | Medical prognosis | Mortality | Endocrine therapy | Mammography | Kinases | Cancer therapies | Tumors | Index Medicus
Journal Article